Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle.
JAMA Neurol. 2021 Oct 1;78(10):1236-1248. doi: 10.1001/jamaneurol.2021.2598.
Juvenile amyotrophic lateral sclerosis (ALS) is a rare form of ALS characterized by age of symptom onset less than 25 years and a variable presentation.
To identify the genetic variants associated with juvenile ALS.
DESIGN, SETTING, AND PARTICIPANTS: In this multicenter family-based genetic study, trio whole-exome sequencing was performed to identify the disease-associated gene in a case series of unrelated patients diagnosed with juvenile ALS and severe growth retardation. The patients and their family members were enrolled at academic hospitals and a government research facility between March 1, 2016, and March 13, 2020, and were observed until October 1, 2020. Whole-exome sequencing was also performed in a series of patients with juvenile ALS. A total of 66 patients with juvenile ALS and 6258 adult patients with ALS participated in the study. Patients were selected for the study based on their diagnosis, and all eligible participants were enrolled in the study. None of the participants had a family history of neurological disorders, suggesting de novo variants as the underlying genetic mechanism.
De novo variants present only in the index case and not in unaffected family members.
Trio whole-exome sequencing was performed in 3 patients diagnosed with juvenile ALS and their parents. An additional 63 patients with juvenile ALS and 6258 adult patients with ALS were subsequently screened for variants in the SPTLC1 gene. De novo variants in SPTLC1 (p.Ala20Ser in 2 patients and p.Ser331Tyr in 1 patient) were identified in 3 unrelated patients diagnosed with juvenile ALS and failure to thrive. A fourth variant (p.Leu39del) was identified in a patient with juvenile ALS where parental DNA was unavailable. Variants in this gene have been previously shown to be associated with autosomal-dominant hereditary sensory autonomic neuropathy, type 1A, by disrupting an essential enzyme complex in the sphingolipid synthesis pathway.
These data broaden the phenotype associated with SPTLC1 and suggest that patients presenting with juvenile ALS should be screened for variants in this gene.
青少年肌萎缩侧索硬化症(ALS)是一种罕见的 ALS 形式,其特征是发病年龄小于 25 岁,表现形式多样。
确定与青少年 ALS 相关的遗传变异。
设计、地点和参与者:在这项多中心基于家族的遗传研究中,对一组诊断为青少年 ALS 和严重生长迟缓的无关联患者进行了 trio 全外显子组测序,以确定疾病相关基因。患者及其家属于 2016 年 3 月 1 日至 2020 年 3 月 13 日在学术医院和政府研究机构招募,并观察至 2020 年 10 月 1 日。全外显子组测序也在一系列青少年 ALS 患者中进行。共有 66 名青少年 ALS 患者和 6258 名成年 ALS 患者参与了这项研究。根据诊断选择患者进行研究,所有符合条件的参与者均被纳入研究。所有参与者均无神经障碍家族史,提示新生变异为潜在遗传机制。
仅在索引病例中存在而不在未受影响的家庭成员中存在的新生变异。
对 3 名诊断为青少年 ALS 的患者及其父母进行了 trio 全外显子组测序。随后对 63 名青少年 ALS 患者和 6258 名成年 ALS 患者进行了 SPTLC1 基因变异筛查。在 3 名诊断为青少年 ALS 和生长不良的无关联患者中发现了 SPTLC1 中的新生变异(2 名患者为 p.Ala20Ser,1 名患者为 p.Ser331Tyr)。在无法获得父母 DNA 的青少年 ALS 患者中发现了第四个变异(p.Leu39del)。该基因中的变异以前被证明与常染色体显性遗传性感觉自主神经病 1A 相关,通过破坏鞘脂合成途径中的一个必需酶复合物。
这些数据扩大了与 SPTLC1 相关的表型,并表明出现青少年 ALS 的患者应筛查该基因中的变异。